Publication: 3390

Publication: 3390

Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III Estrogen Receptor positive and HER2 negative breast cancer resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

DOI

URL

Google Scholar

Citation:: Cancer Res vol 81 (4 Supplement) GS4-05

Meeting Instance:: SABCS 2020
Year:: 2020
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3910

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:: Genentech, AstraZeneca
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868 (NRG);

Corr. Author:
Authors:: Cynthia X. Ma Vera Suman A. Marilyn Leitch Souzan Sanati Kiran Vij Gary W. Unzeitig Jeremy Hoog Mark Watson Olwen Hahn Joseph Guenther Abigail Caudle Erika Crouch Horacio Maluf Amy Tiersten Monica Mita Wajeeha Razaq Tina J. Hieken Yang Wang Travis Dockter Jo Anne Zujewski Anna Weiss Kelly Hunt Clifford Hudis Eric P. Winer Matthew J. Ellis Lisa A. Carey Ann H. Partridge

Networks:: CA016, KY015, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC007, LAPS-NY016, LAPS-OK003, LAPS-TX011, LAPS-TX035, NEWMEXICO, NY021, NY167, TX041, TX190

Study: Alliance-A011106
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: